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ABSTRACT
Background. Respiratory complications of solid organ transplant (SOT) are a diagnostic
and therapeutic challenge when requiring intensive care unit (ICU) admission. We aimed
at describing this challenge in a prospective cohort of SOT recipients admitted in the ICU.
Methods. In this post hoc analysis of an international cohort of immunocompromised
patients admitted in the ICU for an acute respiratory failure, we analyzed all SOT
recipients and compared their severity, etiologic diagnosis, prognosis, and outcome ac-
cording to the performance of an invasive diagnostic strategy (encompassing a fiber-optic
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bronchoscopy and bronchoalveolar lavage), the type of transplanted organ, and the need of
invasive ventilation at day 1.
Results. Among 1611 patients included in the primary study, 142 were SOT recipients
(kidney, n ¼ 73; 51.4%; lung, n ¼ 33; 23.2%; liver, n ¼ 29; 20.4%; heart, n ¼ 7; 4.9%).
Lung transplant recipients were younger than other SOT recipients, and severity did not
differ across type of received organ. An invasive diagnostic strategy was more frequently
performed in lung transplant recipients with a trend toward a higher rate of bacterial
etiology in lung than kidney transplant recipients. Overall ICU survival of SOT recipients
was 75.4%. Invasive diagnostic strategy, type of transplanted organ, and need of invasive
mechanical ventilation at day 1 did not affect ICU prognosis.
Conclusions. ICU management of hypoxemic acute respiratory failure in SOT recipients
translated into a low ICU mortality rate, whatever the transplanted organ or the acute
respiratory failure cause. The post-ICU burden of acute respiratory failure SOT recipients
remains to be investigated.
SOLID organ transplant (SOT) is a key therapy inchronic end-stage organ failure and provides a benefit
in terms of quality of life at the price of life-threatening
complications, may they be transplant specific or not.
However, each type of SOT carries an elevated risk for
pulmonary injury [1], either related to their immunosup-
pressive regimens and infectious events or to other type of
complications, that is, pulmonary edema, primary graft
dysfunction, diffuse alveolar hemorrhage, drug-related pul-
monary toxicity, or acute interstitial pneumonia from
various causes [2]. The specific diagnostic workup may be
challenging because the effects of immunosuppression may
dampen the symptoms of infection [3]. In some cases,
clinical presentation of infectious or noninfectious causes of
acute respiratory failure (ARF) may widely overlap. In
other patients, noninfectious causes of ARF may be asso-
ciated with infectious ones. Hence, managing SOT
recipients with ARF includes both a specific diagnostic
workup and a dedicated oxygenation strategy. The diag-
nostic strategy might be invasive, including a fiber-optic
bronchoscopy and bronchoalveolar lavage (FO-BAL) with
the risk of worsening the respiratory status [4] or noninva-
sive, using sputum examinations and/or serum and urine
samples. The early oxygenation challenge includes
noninvasive ventilation (NIV) [5] or high-flow nasal cannula
(HFNC) oxygen [6e8]. Nevertheless, 2 recent studies in
immunocompromised patients with ARF showed that
neither NIV [7] nor HFNC [6] therapy significantly decrease
day 28 mortality or the need for intubation compared with
conventional oxygen therapy (COT). Furthermore, it has
been suggested that a delayed assessment of HFNC failure
might cause a worse clinical outcome in patients with
ARF [9,10].
Data focusing on pulmonary complications and diagnostic
and therapeutic strategies in critically ill SOT recipients are
scarce [11,12]. In the present study, we therefore aimed to
describe the diagnostic strategy, the clinical and etiologic
patterns, and the outcomes of ARF requiring intensive care
unit (ICU) admission in SOT recipients and explore them
according to the type of organ received.
METHODS
Study Design
We conducted a post hoc analysis of the previously published
EFRAIM cohort study [13]. In brief, EFRAIM was a multinational,
observational, prospective cohort study performed by the Nine-I
(caring for critically ill immunocompromised patients) study
group. This group includes critical care physicians from 16 countries
who have extensive experience in the management of various
groups of critically ill immunocompromised patients. Physician
participation was voluntary, without financial incentive. Partici-
pating providers obtained Institutional Review Board approval
from their institutions in accordance with local ethics regulations.
Inclusion criteria were 18 years or older; acute hypoxemic
respiratory failure (PaO2 < 60 mm Hg or oxygen saturation
as measured by pulse oximetry < 90% on room air, tachypnea
> 30/min, or labored breathing or respiratory distress or dyspnea
at rest or cyanosis); need for more than 6 L/min oxygen; respira-
tory symptom duration less than 72 hours; and being nonrelated to
a viral AIDS, that is, hematologic malignant neoplasm or solid
tumor (active or in remission for less than 5 years, including re-
cipients of autologous or allogeneic stem cell transplant), SOT,
long-term (> 30 days) or high-dose (> 1 mg/kg/d) steroids, or any
immunosuppressive drug for more than 30 days. Exclusion criteria
included postoperative ARF (within 6 days of surgery), admission
after a cardiac arrest, ICU admission only to secure FO-BAL, or
refusal of the patient or family to participate in the study. Primary
endpoints of the EFRAIM study [13] were the need for invasive
mechanical ventilation (IMV) in patients not intubated on ICU
admission and all-cause hospital mortality.
After Institutional Review Board approval at each center,
participating ICUs enrolled patients between November 5, 2015,
and July 1, 2016. A standardized paper case report was prepared by
investigators and tested in 35 patients. After feedback and correc-
tions, the case report form was sent to participating ICUs, and once
completed, it was sent back to the coordinating center in Paris for
data entry by specialized technicians used to handling data on
critically ill immunocompromised patients. The study was funded by
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the Groupe de Recherche en Reanimation Respiratoire Onco-
Hématologique, an academic not-for-profit French organization.
Patients
Patients included in EFRAIM study and having SOT, irrespective
of concurrent immune defect, were included in this post hoc anal-
ysis (Fig 1).
Study Procedures
All management decisions were independently made by the
attending physicians according to standard practice in each ICU.
Diagnostic tests to identify the cause of respiratory failure were
noninvasive (blood and sputum cultures for bacteria and fungi,
serum and urine antigens, polymerase chain reaction in blood,
serum sample and nasopharyngeal aspirates, high-resolution
computed tomography scan, echocardiography, serology, and spe-
cific tests according to each situation) or invasive when it encom-
passed FO-BAL.
All diagnoses were reviewed by 2 study investigators for coher-
ence and for alignment with established definitions. COT was
defined as the use of oxygen up to 15 L/min via nasal prongs or
nonrebreathing mask. Oxygenation modalities and the use of NIV
or HFNC were at the discretion of the primary team. Management
of associated organ dysfunction and handling of immunosuppressive
drugs or chemotherapy were done as per local preferences. The
decision to intubate was not controlled by the study.
Patients were enrolled immediately at ICU admission, and the
data in the tables and figures were collected prospectively using the
paper case report form. Patient severity was defined according to
Sequential Organ Failure Assessment (SOFA) score, recorded
within 24 hours of admission, with higher score being associated
with higher number or severity of organ dysfunction and with higher
mortality [14]. Our primary endpoint was the description of the
etiologies and outcomes of ARF in SOT recipients. Our secondary
endpoints were the comparison of their epidemiologic characteris-
tics, their prognosis according to the transplanted organ, and their
prognosis according to the need of IMV at day 1, the lack of
etiologic diagnosis, and the use of FO-BAL in the diagnosis
strategy.
STATISTICAL ANALYSIS
Quantitative variables were described as median (inter-
quartile range [IQR]) and were compared between groups
using the nonparametric Wilcoxon rank-sum test. Qualita-
tive variables were described as frequency (percentages) and
were compared between groups using Fisher exact test.
Logistic regression model were used to assess factors
independently associated with mortality. We used condi-
tional stepwise regression with .2 as the critical P value for
entry into the model and .1 as the P value for removal. It
was planned a priori to force transplanted organ, IMV at
day 1, lack of etiologic diagnosis, and use of FO-BAL in the
final model should these variables not be selected.
Interactions and correlations between the explanatory var-
iables were carefully checked. Continuous variables for
which log-linearity was not confirmed were transformed into
categorical variables according to median or IQR. The final
models were assessed by calibration, discrimination, and
relevancy. Residuals were plotted, and the distributions
were inspected. To adjust for center effect, a mixed model
was then performed using variables previously selected,
using center as random effect on the intercept. This model
adjusting for clustering effect was planned a priori to be the
main result of the analysis. The same validation methods
were used as previously. Adjusted odds ratios (OR) of
variables present in the final model are presented with their
95% confidence intervals.
Kaplan-Meier graphs were used to express the probability
of death from inclusion to hospital discharge, censored at
day 90. Influence of the transplanted organ, use of FO-BAL
(ie, an invasive diagnostic strategy), oxygenation strategy at
day 1, and lack of etiologic diagnosis for respiratory failure
were assessed by the log-rank test.
All analyses were 2-sided, and a P value < .05 was
considered significant. Statistical analyses were performed
with R statistical software version 3.4.3 (The R Foundation
for Statistical Computing, Vienna, Austria) and packages
Survival, lme4, and lmerTest.
RESULTS
Among the 1611 immunocompromised patients with ARF
enrolled over the 8-month period in the 68 participating
ICUs, 142 (8.9%) were solid organ recipients. Kidney
Fig 1. Flow chart of the included patients. Among 1611 immunocompromised patients enrolled over the 8-month period in the 68
participating ICUs admitted for an acute respiratory failure, 142 (8.9%) were solid organ recipients (n ¼ 73 kidney recipients; n ¼ 33
lung recipients; n ¼ 29 liver recipients; and n ¼ 7 heart recipients) included in this post hoc series.
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recipients accounted for 73 patients (51.4%), followed by
lung recipients (n ¼ 33; 23.2%), liver recipients (n ¼ 29;
20.4%), and heart recipients (n ¼ 7; 4.9%) (Fig 1). Their
main demographics and comorbid conditions are detailed in
Tables 1 and 2. Briefly, they were aged 62.0 (range,
55.0-68.0) years, and women accounted for 40.7% of those.
Of note, lung transplant recipients were younger than other
organ recipients, and liver recipients were less frequently
female than other organ recipients (1.3% vs 46.9%;
P ¼ .004).
ICU Admission
Severity, as addressed by the SOFA score, did not signifi-
cantly differ across different types of transplants. Vaso-
pressors and renal replacement therapy were applied during
the first 7 days of ICU stay for 55.6% and 26.1% of SOT
recipients, respectively, without significant difference ac-
cording to the transplanted organ.
ARF Etiologies
Diagnostic strategies differed, as an invasive strategy was
performed in 2 heart (28.6%), 27 kidney (37.0%), 19 liver
(65.5%), and 23 lung (69.7%) recipients (P ¼ .003). The
final diagnosis of the respiratory failure episodes did not
significantly differ according to the transplanted organ
(Table 1). In brief, bacterial ARF accounted for 42 cases
(29.6%) with a trend toward higher bacterial etiologies in
lung transplant recipients (n ¼ 16; 48.5% vs n ¼ 1; 14.3% in
heart; n ¼ 18; 24.7% in kidney; and n ¼ 7; 24.1% in liver
transplant recipients; P ¼ .052). A virus was the second
cause for ARF in 25 patients (17.6%) followed by cardiac
failure in 11 (7.7%). Finally, the cause remained







Recipients n ¼ 7
Kidney transplant
Recipients n ¼ 73
Liver Transplant
Recipients n ¼ 29
Lung Transplant
Recipients n ¼ 33 P Value
Age, median (IQR), y 62.0 (55.0-68.0) 63.00 (49.0-68.5) 64.0 (58.0-72.0) 61.0 (56.0-67.0) 57.0 (47.0-62.0) < .001
Sex, No. (%), F 57 (40.7) 2 (28.6) 37 (51.4) 4 (14.3) 14 (42.4) .007
Comorbid conditions at ICU admission,
No. (%)
- Solid tumor 24 (16.9) 0 14 (19.2) 7 (24.1) 3 (9.1) .24
- Hematologic malignant neoplasm 8 (5.6) 0 7 (9.6) 1 (3.4) 1 (3) .81
- Hematological stem cell or bone
marrow transplant
1 (0.7) 0 1 (1.4) 0 0 .81
- Diabetes mellitus 57 (42.2) 4 (57.1) 28 (39.4) 13 (50) 12 (38.7) .64
- Chronic kidney disease 85 (61.2) 6 (85.7) 57 (79.2) 14 (50) 8 (25) < .001
- Cirrhosis 21 (15.4) 0 3 (4.2) 17 (63) 1 (3.2) < .001
ECOG performance status, median (IQR) 1 (1-2) 1 (1-2) 1 (1-2) 2 (1-2) 2 (1-2) .76
SOFA at ICU admission, median (IQR) 6 (4.0-10.0) 9 (5.5-11.0) 5.0 (3.0-10.0) 7.0 (5.0-11.0) 7.0 (4.0-9.0) .272
Therapies administered during the first
7 days of ICU stay, No. (%)
- Vasopressors 79 (55.6) 3 (42.9) 35 (47.9) 21 (72.4) 20 (60.6) .12
- Renal replacement therapy 37 (26.1) 3 (42.9) 18 (24.7) 6 (20.7) 10 (30.3) .61
Oxygenation strategy at day 1, No. (%)* .092
- Conventional oxygen therapy 69 (48.6) 4 (57.1) 42 (57.5) 11 (37.9) 12 (36.4)
- High-flow nasal cannula oxygen 18 (12.7) 1 (14.3) 6 (8.2) 2 (6.9) 9 (27.3)
- Noninvasive ventilation 22 (15.5) 0 12 (16.4) 6 (20.7) 4 (12.1)
- Invasive ventilation 33 (23.2) 2 (28.6) 13 (17.8) 10 (34.5) 8 (24.2)
Patients who underwent FO-BAL during
the etiologic workup, No. (%)
71 (50.0) 2 (28.6) 27 (37.0) 19 (65.5) 23 (69.7) .003
ARF etiology, No. (%)
- Bacterial 42 (29.6) 1 (14.3) 18 (24.7) 7 (24.1) 16 (48.5) .052
- Pneumocystis pneumonia 6 (4.2) 0 5 (6.8) 1 (3.4) 0 .38
- Virus 25 (17.6) 2 (28.6) 13 (17.8) 3 (10.3) 7 (21.2) .59
- Candida 2 (1.4) 0 1 (1.4) 1 (3.4) 0 .70
- Invasive pulmonary aspergillosis 10 (7.0) 0 6 (8.2) 2 (6.9) 2 (6.1) .87
- Cardiac failure 11 (7.7) 1 (14.3) 7 (9.6) 2 (6.9) 1 (3.0) .61
- Unknown 25 (17.6) 2 (28.6) 13 (17.8) 2 (6.9) 8 (24.2) .27
Alive at ICU discharge, No. (%) 107 (75.4) 6 (85.7) 59 (80.8) 21 (72.4) 21 (63.6) .24
Alive at hospital discharge, No. (%) 88 (63.3) 5 (83.3) 50 (68.5) 17 (60.7) 16 (50.0) .22
Alive at day 90, No. (%) 69 (55.2) 5 (71.4) 41 (62.1) 12 (50.0) 11 (39.3) .16
Abbreviations: ARF, acute respiratory failure; ECOG, Eastern Cooperative Oncology Group; F, female; FO-BAL, fiber-optic bronchoscopy and bronchoalveolar
lavage; ICU, intensive care unit; IQR, interquartile range (25-75); SOFA, Sequential Organ Failure Assessment.
*Various oxygenation strategies might have been used for a single patient.
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undetermined in 25 patients, with no differences across the
different types of transplants (17.5%).
Prognosis and Outcome
In total, 107 patients (75.4%) were alive at ICU discharge, 88
(63.3%) were alive at hospital discharge, and 69 (55.2%) were
alive at day 90 after admission without significance difference
according to theorgan received (respectively for ICU,hospital,
and day 90 survival: P ¼ .24, P ¼ .22, and P ¼ .16). Before
adjustment, undetermined ARF etiology, use of specific
oxygenation strategy, type of transplant, and FO-BAL per-
formance were not associated with survival (Fig 2).
Using a hierarchical model and adjusting for center
effect, mortality was associated with SOFA score and pre-
existing chronic kidney disease (Table 3). When forced 1
by 1 in the final model, transplanted organ (OR vs renal
transplant, respectively, 0.21 [95% CI, 0.02-2.48], 0.90 [95%
CI, 0.30-2.69], and 1.68 [95% CI, 0.58-4.84] for heart, liver,
and lung transplants), undetermined ARF etiology (OR,
2.09; [95% CI, 0.60-7.25]), FO-BAL not performed (OR,
0.56; [95% CI, 0.23-1.36]), and oxygenation strategy at ICU
admission (OR vs HFNC, respectively, 1.27 [95% CI,
0.30-5.31], 1.06 [95% CI, 0.18-6.37], and 2.21 [95% CI,
0.43-11.29] for COT, NIV, and IMV) were neither selected
nor did they changed the final model.
DISCUSSION
The present study is one of the largest studies focusing on
ARF in SOT recipients [11]. From this post hoc analysis of
the EFRAIM cohort [13], some important findings
emerged. Above all, critically ill SOT recipients with ARF
are of particular severity according to their high SOFA
scores and the high rate of organ supply throughout the first
7 days following ICU admission as well as the high mortality
rates at ICU discharge or at day 90. Second, even though
Table 2. Demographic Data, Comorbid Conditions, Severity and ICU Course of the 142 Solid Organ Transplant Recipients According to
Status at Hospital Discharge
Variables
Death at Hospital
Discharge n ¼ 51
Alive at Hospital
Discharge n ¼ 88 P Value
Age, median (IQR), y 62.0 (56.0-70.0) 61.00 (55.0-68.0) .701
Sex, No. (%), F 21 (42.0) 35 (40.2) .982
Comorbid conditions at ICU admission, No. (%)
- Solid tumor 8 (15.7) 16 (18.2) .887
- Hematologic malignant neoplasm 5 (9.8) 3 (3.4) .190
- Hematologic stem cell or bone marrow transplant 0 1 (1.1) > .99
- Diabetes mellitus 20 (40.0) 36 (43.9) .796
- Chronic kidney disease 27 (52.9) 57 (67.1) .145
- Cirrhosis 10 (20.4) 11 (13.1) .358
ECOG performance status, median (IQR) 2 (1-3) 1 (1-2) .066
SOFA at ICU admission, median (IQR) 9 (4.0-11.0) 5 (3.5-8.0) .007
Therapies administered during the first 7 days of ICU stay, No. (%)
- Vasopressors 38 (74.5) 39 (44.3) .001
- Renal replacement therapy 18 (35.3) 19 (21.6) .12
Oxygenation strategy at day 1, No. (%)* .07
- Conventional oxygen therapy 21 (41.2) 48 (54.5)
- High-flow nasal cannula oxygen 5 (9.8) 12 (13.6)
- Noninvasive ventilation 7 (13.7) 14 (15.9)
- Invasive mechanical ventilation 18 (35.3) 14 (15.9)
Patients who underwent a FO-BAL during the etiologic workup, No. (%) 31 (60.8) 39 (44.3) .09
ARF etiology, No. (%)
- Bacterial 15 (29.4) 25 (28.4) > .99
- Pneumocystis pneumonia 2 (3.9) 4 (4.5) > .99
- Virus 9 (17.6) 16 (18.2) > .99
- Candida 1 (2.0) 1 (1.1) > .99
- Cardiac failure 2 (3.9) 9 (10.2) .32
- Unknown 12 (23.5) 12 (13.6) .21
Transplanted organ, No. (%) .221
- Heart 1 (2.0) 5 (5.7)
- Kidney 23 (45.1) 50 (56.8)
- Liver 11 (21.6) 17 (19.3)
- Lung 16 (31.4) 16 (18.2)
Alive at ICU discharge, No. (%) 16 (31.4) 88 (85.7) -
Alive at day 90, No. (%) 0 69 (94.5) -
Abbreviations: ARF, acute respiratory failure; ECOG, Eastern Cooperative Oncology Group; F, female; FO-BAL, fiber-optic bronchoscopy and bronchoalveolar
lavage; ICU, intensive care unit; IQR, interquartile range (25-75); SOFA, Sequential Organ Failure Assessment.
*Various oxygenation strategies might have been used for a single patient.
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lung transplant recipients were more frequently investigated
with FO-BAL, an invasive diagnosis strategy was not asso-
ciated with improved survival in the multivariable analysis.
Finally, we did not find any survival difference between
noninvasive oxygenation technique (NIV, COT, HFNC).
Chronic kidney disease has been significantly associated
with better survival. It has to be underlined that, in com-
parison with other organ dysfunction, kidney failure can be
easily treated with renal replacement therapy in case of a
renal graft lost. In case of lung, hepatic, or cardiac graft
dysfunction, only a new graft might allow a sustainable
treatment of graft dysfunction. Although we did not evi-
dence any significant differences in mortality rates accord-
ing to the transplanted organs, chronic kidney disease might
simply be a surrogate for the better prognosis of renal
transplant recipients in the ICU. The observed survival of
81.1% at ICU discharge is in line with the 77.5% reported
by Canet et al [11] in their 9-center French series. Of note in
this series, 74.2% of them were dialysis free at day 90.
We found that mortality was not increased in patients
remaining with an undetermined ARF etiology. One can
infer that some of the nondocumented episodes were, in
fact, pneumonia empirically treated. In case of respiratory
failure occurring in profoundly immunocompromised pa-
tients, such as in SOT, first-line therapy encompasses an
early broad-spectrum antimicrobial treatment. In that case,
the absence of a documented microbial etiology does not
rule out a bacterial cause. This is in line with the low
number of patients with opportunistic infection or nonin-
fectious pulmonary involvement. Another explanation to
these findings might be the lack of statistical power.
The type of respiratory support at day 1 has not been
found to be related to the mortality. As shown in Fig 2, no
significant difference could be found in mortality according
to ventilatory strategy. However, there was a trend toward
higher mortality rate in patients having received mechanical
ventilation. It is worth pointing that ICU survival was not
affected by the noninvasive therapeutic strategy (HFNC,
COT, NIV). These results are in line with those previously
published by Lemiale et al [7] and Azoulay et al [6] showing
that among immunocompromised patients admitted to the
ICU with hypoxemic ARF, early noninvasive ventilation or
HFNC compared with oxygen therapy alone did not
improve survival.
In the present study, ICU survival was not affected by a
noninvasive diagnosis strategy (ie, without the performance
of FO-BAL) or by a determined ARF etiology. However,
FO-BAL performance had no deleterious effect on mor-
tality. These findings are highly consistent with those of
prior series of immunocompromised patients admitted in
the ICU for an ARF in which an invasive strategy was not
associated with an increased survival or a higher diagnosis
Fig 2. Cumulative survival of the transplant recipients according to (A) the performance of a bronchoalveolar lavage in the diagnostic
strategy; (B) the obtention of a final diagnosis of the respiratory failure; (C) the oxygenation strategy at day 1; and (D) the type of trans-
planted organ. COT, conventional oxygen therapy; FO-BAL, fiber-optic bronchoscopy and bronchoalveolar lavage; HFNC, high-flow
nasal cannula oxygen therapy; IMV, invasive mechanical ventilation; NIV, noninvasive ventilation.
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rate [15,16]. Nevertheless, noninvasive strategies vs invasive
strategies have mostly been evaluated in patients receiving
oncohematologic treatment. Although the data we report
are in this line, whether this strategy may be extended to
SOT recipients remains to be investigated. Furthermore,
performing a fiber-optic bronchoscopy might be necessary
to determine specific causes of respiratory failure, such as
airway complications in lung transplant recipients or bron-
chial Kaposi sarcoma, or to perform transbronchial biopsies,
given the possible diagnosis [12]. Hence, we suggest not to
avoid FO-BAL when needed in patients with high proba-
bility of Pneumocystis pneumonia, drug-related pulmonary
toxicity, pulmonary graft rejection, or interstitial involve-
ment with no obvious cause, given the fact that FO-BAL is
probably safe in this population.
We found an overall ICU mortality of 24.6%, similar to
mortality of all-causes immunodepression, in the Princeps
publication [13]. ICU mortality was higher for lung trans-
plant recipients (36.4%) and lower for heart transplant re-
cipients (14.3%). Mortality rate of lung transplant recipients
rises to 60.7% after 90 days of ICU admission, highlighting
the severe prognosis of an ARF episode in this setting.
Various recent prospective cohorts investigated the prog-
nosis of lung transplant recipients with a viral infection
[17,18]. Respiratory virus positive testing has been signifi-
cantly associated with the occurrence of acute rejection,
while a viral lower respiratory tract infection was a risk
factor for subsequent Pseudomonas aeruginosa infection or
colonization [17]. Moreover, the occurrence of a viral lower
respiratory tract infection has been an independent risk
factor for the development of chronic lung allograft
dysfunction [18].
Kidney transplant recipient mortality after an ARF
episode requiring ICU admission had been reported in the
multicenter study performed by Canet et al [11]. In this
study, ICU mortality reached 18%, which is consistent with
our results (19.2% in our cohort).
In spite of its large and multicenter design, our study
bears some limitations. First, the post hoc analysis of these
prospectively collected data explains the limited available
results when focusing on each single transplanted organ.
Indeed, as the initial cohort encompassed a wide spectrum
of immunodeficiencies [13], collected data were not specif-
ically designed for SOT recipients. Thus, timing to organ
transplant and the immunosuppressive regimen were not
available and were not adjusted for. In addition, as per the
study design, it was impossible to interpret or assess prog-
nostic influence of delayed IMV initiation. In the same line,
although no prognostic influence of transplanted organ
could be demonstrated, sample size was limited, and lack of
statistical power may account for these negative findings.
Last, we could not identify those SOT recipients in whom
FO-BAL could bear a high diagnostic or therapeutic yield.
CONCLUSIONS
ICU management of hypoxemic ARF in SOT recipients
translated into a low ICU mortality rate, whatever the
transplanted organ or the ARF cause. In this setting,
although an invasive strategy with FO-BAL is not associated
with a better prognosis, neither was it associated with a
higher mortality.
The high 3-month mortality, especially in lung transplant
recipients, urges reinforcement of post-ICU care in this
setting. Studies to improve a rapid diagnosis of ARF, a
prompt management of SOT recipients, and the analysis of
the long-term consequences of ARF, especially in lung
transplant recipients, are warranted.
REFERENCES
[1] De Gasperi A, Feltracco P, Ceravola E, Mazza E. Pulmonary
complications in patients receiving a solid-organ transplant. Curr
Opin Crit Care 2014;20:411e9.
[2] Kotloff RM, Ahya VN, Crawford SW. Pulmonary complica-
tions of solid organ and hematopoietic stem cell transplantation.
Am J Respir Crit Care Med 2004;170:22e48.
[3] Fishman JA. From the classic concepts to modern practice.
Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis
2014;20(Suppl. 7):4e9.
[4] Cracco C, Fartoukh M, Prodanovic H, Azoulay E,
Chenivesse C, Lorut C, et al. Safety of performing fiberoptic
bronchoscopy in critically ill hypoxemic patients with acute respi-
ratory failure. Intensive Care Med 2013;39:45e52.
[5] Antonelli M, Conti G, Bufi M, Costa MG, Lappa A,
Rocco M, et al. Noninvasive ventilation for treatment of acute
respiratory failure in patients undergoing solid organ trans-
plantation: a randomized trial. JAMA 2000;283:235e41.
[6] Azoulay E, Lemiale V, Mokart D, Nseir S, Argaud L, Pène F,
et al. Effect of high-flow nasal oxygen vs standard oxygen on 28-day
mortality in immunocompromised patients with acute respiratory
failure: the HIGH randomized clinical trial. JAMA 2018;320:2099.
[7] Lemiale V, Mokart D, Resche-Rigon M, Pène F, Mayaux J,
Faucher E, et al. Effect of noninvasive ventilation vs oxygen therapy
on mortality among immunocompromised patients with acute res-
piratory failure: a randomized clinical trial. JAMA 2015;314:1711.
[8] Roca O, de Acilu MG, Caralt B, Sacanell J, Masclans JR.
Humidified high flow nasal cannula supportive therapy improves
outcomes in lung transplant recipients readmitted to the intensive
care unit because of acute respiratory failure. Transplantation
2015;99:1092e8.
[9] Kang BJ, Koh Y, Lim CM, Huh JW, Baek S, Han M, et al.
Failure of high-flow nasal cannula therapy may delay intubation and
increase mortality. Intensive Care Med 2015;41:623e32.
[10] Ricard JD, Messika J, Sztrymf B, Gaudry S. Impact on
outcome of delayed intubation with high-flow nasal cannula
Table 3. Final Hierarchical Logistic Regression Reporting
Factors Independently Associated With Hospital
Mortality (95% CI)
Variables OR (95% CI) P Value
SOFA score per point 1.19 (1.06-1.33) .003
Chronic kidney disease 0.26 (0.09-0.71) .03
ECOG 0 Reference -
ECOG 1 2.14 (0.55-7.21) .26
ECOG 2 1.70 (0.40-7.21) .49
ECOG 3 4.26 (0.91-20.06) .067
Center effect was included as a random effect on the intercept. Hosmer-
Lemeshow goodness of fit: c2 ¼ 3.27; P ¼ .917; C-stat ¼ 0.70 (95% CI, 0.61-
0.79).
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology
Group; OR, odds ratio; SOFA, Sequential Organ Failure Assessment.
2986 MESSIKA, DARMON, MAL ET AL
oxygen: is the device solely responsible? Intensive Care Med
2015;41:1157e8.
[11] Canet E, Osman D, Lambert J, Guitton C, Heng AE,
Argaud L, et al. Acute respiratory failure in kidney transplant re-
cipients: a multicenter study. Crit Care Lond Engl 2011;15:R91.
[12] Mazo C, Pont T, Ballesteros MA, López E, Rellán L,
Robles JC, et al. Pneumonia vs graft dysfunction as the cause of
acute respiratory failure after lung transplant: a 4-year multicenter
prospective study in 153 adults requiring intensive care admission.
Eur Respir J 2019;54.
[13] Azoulay E, Pickkers P, Soares M, Perner A, Rello J,
Bauer PR, et al. Acute hypoxemic respiratory failure in immuno-
compromised patients: the EFRAIM multinational prospective
cohort study. Intensive Care Med 2017;43:1808e19.
[14] Vincent JL, Moreno R, Takala J, Willatts S, De
Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ
Failure Assessment) score to describe organ dysfunction/failure. On
behalf of the Working Group on Sepsis-Related Problems of the
European Society of Intensive Care Medicine. Intensive Care Med
1996;22:707e10.
[15] Azoulay E, Mokart D, Rabbat A, Pene F, Kouatchet A,
Bruneel F, et al. Diagnostic bronchoscopy in hematology and
oncology patients with acute respiratory failure: prospective multi-
center data. Crit Care Med 2008;36:100e7.
[16] Azoulay E, Mokart D, Lambert J, Lemiale V, Rabbat A,
Kouatchet A, et al. Diagnostic strategy for hematology and
oncology patients with acute respiratory failure: randomized
controlled trial. Am J Respir Crit Care Med 2010;182:1038e46.
[17] Peghin M, Hirsch HH, Len Ó, Codina G, Berastegui C,
Sáez B, et al. Epidemiology and immediate indirect effects of res-
piratory viruses in lung transplant recipients: a 5-year prospective
study. Am J Transplant 2017;17:1304e12.
[18] Peghin M, Los-Arcos I, Hirsch HH, Codina G, Monforte V,
Bravo C, et al. Community-acquired respiratory viruses are a risk
factor for chronic lung allograft dysfunction. Clin Infect Dis
2019;69:1192e7.
SOLID ORGAN TRANSPLANT RESPIRATORY FAILURE 2987
